<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807741</url>
  </required_header>
  <id_info>
    <org_study_id>2012-4181</org_study_id>
    <nct_id>NCT01807741</nct_id>
  </id_info>
  <brief_title>Asenapine for Bipolar Depression</brief_title>
  <official_title>Asenapine for Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare asenapine with placebo in the treatment of depression&#xD;
      associated with bipolar disorder, type I over eight weeks.&#xD;
&#xD;
      We hypothesize that patients will show significantly greater improvement with asenapine than&#xD;
      placebo over eight weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      86 patients with an episode of major depression associated with bipolar disorder, type I will&#xD;
      be recruited by two sites for the study over fifteen months. Medication will be administered&#xD;
      in a double-blind manner. Patients will receive asenapine (or placebo) beginning on day 0 at&#xD;
      5 mg bid. Dose may be increased to 10 mg bid and adjusted based on clinical response.&#xD;
      Patients will be evaluated by a blinded (to treatment status) rater. Patients will be seen&#xD;
      and ratings obtained at baseline (day 0) and on days 7, 14, 28, 42, and 56 (or termination&#xD;
      from the study). Adverse events will be evaluated as well.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    funding ended due to recruitment delays&#xD;
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Depression Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Montgomery-Asberg Depression Rating Scale (MADRS)will be used as a measure of efficacy reflecting change in MADRS total scores from baseline to endpoint over 8 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Depression Response Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>MADRS Response Rate: Defined by a ≥ 50% decrease from baseline to endpoint in MADRS total score over 8 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Asenapine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asenapine will be given beginning on day 0 at 5 mg bid. Dose will be increased to 10 mg bid if there is less than 50% decrease in MADRS score by week 2. Dose increases may be held if clinically indicated. Doses may be decreased at any time, if clinically indicated, by increments of 5 mg/day to a minimum of 5 mg qHS. Daily treatment with asenapine will be for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sublingual tablets similar to the asenapine tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine</intervention_name>
    <description>Available in 5 and 10 mg.</description>
    <arm_group_label>Asenapine Group</arm_group_label>
    <other_name>Saphris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet criteria for bipolar depression based on the MINI and confirmation of a previous&#xD;
             manic or mixed episode&#xD;
&#xD;
          -  18-55 years of age&#xD;
&#xD;
          -  Female patients must be using a medically accepted means of contraception (e.g. oral&#xD;
             contraceptives, Depo-Provera, abstinence)&#xD;
&#xD;
          -  Each patient must understand the nature of the study and must provide written informed&#xD;
             consent&#xD;
&#xD;
          -  Patients must have a diagnosis of bipolar disorder, type I and currently display an&#xD;
             acute depressive episode as determined by M.I.N.I. (Sheehan et al, 1998)&#xD;
&#xD;
          -  Patients must have a baseline (day 0) MADRS score ≥26&#xD;
&#xD;
          -  Current episode of depression must have persisted for at least one month and no more&#xD;
             than six months at study entry&#xD;
&#xD;
          -  Subjects should be fluent in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are either pregnant or lactating&#xD;
&#xD;
          -  Clinically significant or unstable hepatic, renal, gastroenterologic, respiratory,&#xD;
             cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical&#xD;
             conditions&#xD;
&#xD;
          -  Any history of current or past diabetes that was treated with pharmacological&#xD;
             intervention&#xD;
&#xD;
          -  Neurological disorders including epilepsy, stroke, or severe head trauma&#xD;
&#xD;
          -  Clinically significant laboratory abnormalities, on any of the following tests: CBC&#xD;
             with differential, electrolytes, BUN, creatinine, hepatic transaminases, lipid&#xD;
             profile, fasting glucose, urinalysis, thyroid indices and EKG&#xD;
&#xD;
          -  Depression due to a general medical condition or substance-induced depression (DSM-IV)&#xD;
&#xD;
          -  Mental retardation (IQ &lt;70)&#xD;
&#xD;
          -  Meeting criteria for a mixed episode, as defined by the Diagnostic and Statistical&#xD;
             Manual of Mental Disorders, Fourth Edition (DSM-IV)&#xD;
&#xD;
          -  History of hypersensitivity to or intolerance of asenapine&#xD;
&#xD;
          -  Prior history of asenapine non-response&#xD;
&#xD;
          -  DSM-IV substance (except nicotine or caffeine) dependence within the past 3 months&#xD;
&#xD;
          -  Judged clinically to be at suicidal risk (defined as having active suicidal ideation,&#xD;
             intent or plan, or a serious suicide attempt within 30 days, or a baseline MADRS&#xD;
             suicide score of &gt;4)&#xD;
&#xD;
          -  Participation in a clinical trial of another investigational drug within 1 month (30&#xD;
             days) prior to study entry&#xD;
&#xD;
          -  Failure of the current depressive episode to respond to two or more pharmacological&#xD;
             interventions&#xD;
&#xD;
          -  Treatment with an injectable depot neuroleptic within less than one dosing interval&#xD;
             between depot neuroleptic injections and day 0&#xD;
&#xD;
          -  Schizophrenia or other psychotic disorders (including schizophreniform disorder,&#xD;
             schizoaffective disorder, delusional disorder, brief psychotic disorder, shared&#xD;
             psychotic disorder, psychotic disorder due to a general medical condition,&#xD;
             substance-induced psychotic disorder, psychotic disorder not otherwise specified) as&#xD;
             defined in the DSM-IV&#xD;
&#xD;
          -  Major depressive disorder, dysthymic disorder, depressive disorder not otherwise&#xD;
             specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caleb M Adler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Caleb M. Adler</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asenapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

